(Q33398217)

26 July 2017

title

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia (English)

1 reference

26 July 2017

1 reference

1 reference

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Maxime Berthelot-Richer

1

1 reference

26 July 2017

Brigitte Boilard

2

1 reference

26 July 2017

Annie Morin

3

1 reference

26 July 2017

Brigitte Bolduc

4

1 reference

26 July 2017

Patrice Beauregard

5

1 reference

26 July 2017

Rami Kotb

6

1 reference

26 July 2017

publication date

14 November 2011

1 reference

26 July 2017

1 reference

26 July 2017

volume

52

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

739-741

1 reference

Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

The clinical impact of platelet refractoriness: correlation with bleeding and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

Biology and chemistry of thrombopoietic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

21 January 2018

Thrombopoietic agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03382.X

10.1111/J.1537-2995.2011.03382.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference